A single centre experience of patients with rare cancers referred for early phase clinical trials
Abstract Background Cancers affecting < 6/100,000/year are classified as rare, but they account for up to 25% of all cancers and are associated with worse 5-year survival than common cancers. Early-phase clinical trials (EPCTs) may represent a viable treatment option for patients with rare cancer...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-13934-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850063711715196928 |
|---|---|
| author | Angelos Angelakas Natalie Cook Donna M. Graham Matthew Krebs Fiona Thistlethwaite Louise Carter |
| author_facet | Angelos Angelakas Natalie Cook Donna M. Graham Matthew Krebs Fiona Thistlethwaite Louise Carter |
| author_sort | Angelos Angelakas |
| collection | DOAJ |
| description | Abstract Background Cancers affecting < 6/100,000/year are classified as rare, but they account for up to 25% of all cancers and are associated with worse 5-year survival than common cancers. Early-phase clinical trials (EPCTs) may represent a viable treatment option for patients with rare cancers as they have evolved significantly with novel designs and the increasing use of precision medicine. Methods A retrospective study of patients with rare cancers referred to a large EPCT team at a UK specialist centre over 5 years (2016–2020) was conducted. Patient demographics, medical and oncological history, genomic variants, EPCT participation, responses and survival outcomes were analysed. Results In total, 240 patients with rare cancers were included. The mean age at diagnosis was 51.7 years (range 16–84), 54.2% of the patients were female. The most frequent rare cancers originated from the digestive system (27.1%), female genital tract (20%) and head and neck (H + N) (18.3%). Molecular profiling was offered to 45.5% of the population, median number of gene alterations was 3 per patient (range 1–20) while actionable gene alterations were reported in 60.2% (n = 50) of those with identified gene aberrations. Fifty-one patients participated in EPCTs, with 39.2% achieving SD and 11.8% PR. Median PFS for trial participants was three months (95% CI 1.12 – 4.88) while median OS in the trial patients was 16 months (95% CI 9.10 – 22.90) compared to 7 months for non-trial participants (95% CI 5.50 – 8.51). Finally, poor Royal Marsden Hospital (RMH) prognostic score (2–3) was correlated with worse survival when controlling for age and sex (HR 1.714, 95% CI 1.19 – 2.46, p = 0.004). Conclusions Participation of patients with rare cancers in EPCTs may be associated with a survival benefit and lead to the development of new treatments for these patients. Moreover, expanded use of precision medicine is paramount as it can inform targeted treatment selection in this heterogenous group. |
| format | Article |
| id | doaj-art-392d2aef09694085b7f209691e5ef548 |
| institution | DOAJ |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-392d2aef09694085b7f209691e5ef5482025-08-20T02:49:30ZengBMCBMC Cancer1471-24072025-03-0125111210.1186/s12885-025-13934-2A single centre experience of patients with rare cancers referred for early phase clinical trialsAngelos Angelakas0Natalie Cook1Donna M. Graham2Matthew Krebs3Fiona Thistlethwaite4Louise Carter5Department of Medical Oncology, The Christie NHS Foundation TrustDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, University of ManchesterDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, University of ManchesterDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, University of ManchesterDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, University of ManchesterDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, University of ManchesterAbstract Background Cancers affecting < 6/100,000/year are classified as rare, but they account for up to 25% of all cancers and are associated with worse 5-year survival than common cancers. Early-phase clinical trials (EPCTs) may represent a viable treatment option for patients with rare cancers as they have evolved significantly with novel designs and the increasing use of precision medicine. Methods A retrospective study of patients with rare cancers referred to a large EPCT team at a UK specialist centre over 5 years (2016–2020) was conducted. Patient demographics, medical and oncological history, genomic variants, EPCT participation, responses and survival outcomes were analysed. Results In total, 240 patients with rare cancers were included. The mean age at diagnosis was 51.7 years (range 16–84), 54.2% of the patients were female. The most frequent rare cancers originated from the digestive system (27.1%), female genital tract (20%) and head and neck (H + N) (18.3%). Molecular profiling was offered to 45.5% of the population, median number of gene alterations was 3 per patient (range 1–20) while actionable gene alterations were reported in 60.2% (n = 50) of those with identified gene aberrations. Fifty-one patients participated in EPCTs, with 39.2% achieving SD and 11.8% PR. Median PFS for trial participants was three months (95% CI 1.12 – 4.88) while median OS in the trial patients was 16 months (95% CI 9.10 – 22.90) compared to 7 months for non-trial participants (95% CI 5.50 – 8.51). Finally, poor Royal Marsden Hospital (RMH) prognostic score (2–3) was correlated with worse survival when controlling for age and sex (HR 1.714, 95% CI 1.19 – 2.46, p = 0.004). Conclusions Participation of patients with rare cancers in EPCTs may be associated with a survival benefit and lead to the development of new treatments for these patients. Moreover, expanded use of precision medicine is paramount as it can inform targeted treatment selection in this heterogenous group.https://doi.org/10.1186/s12885-025-13934-2Rare cancersEarly phase trialsReal world dataPrognosisPrecision medicineMolecular profiling |
| spellingShingle | Angelos Angelakas Natalie Cook Donna M. Graham Matthew Krebs Fiona Thistlethwaite Louise Carter A single centre experience of patients with rare cancers referred for early phase clinical trials BMC Cancer Rare cancers Early phase trials Real world data Prognosis Precision medicine Molecular profiling |
| title | A single centre experience of patients with rare cancers referred for early phase clinical trials |
| title_full | A single centre experience of patients with rare cancers referred for early phase clinical trials |
| title_fullStr | A single centre experience of patients with rare cancers referred for early phase clinical trials |
| title_full_unstemmed | A single centre experience of patients with rare cancers referred for early phase clinical trials |
| title_short | A single centre experience of patients with rare cancers referred for early phase clinical trials |
| title_sort | single centre experience of patients with rare cancers referred for early phase clinical trials |
| topic | Rare cancers Early phase trials Real world data Prognosis Precision medicine Molecular profiling |
| url | https://doi.org/10.1186/s12885-025-13934-2 |
| work_keys_str_mv | AT angelosangelakas asinglecentreexperienceofpatientswithrarecancersreferredforearlyphaseclinicaltrials AT nataliecook asinglecentreexperienceofpatientswithrarecancersreferredforearlyphaseclinicaltrials AT donnamgraham asinglecentreexperienceofpatientswithrarecancersreferredforearlyphaseclinicaltrials AT matthewkrebs asinglecentreexperienceofpatientswithrarecancersreferredforearlyphaseclinicaltrials AT fionathistlethwaite asinglecentreexperienceofpatientswithrarecancersreferredforearlyphaseclinicaltrials AT louisecarter asinglecentreexperienceofpatientswithrarecancersreferredforearlyphaseclinicaltrials AT angelosangelakas singlecentreexperienceofpatientswithrarecancersreferredforearlyphaseclinicaltrials AT nataliecook singlecentreexperienceofpatientswithrarecancersreferredforearlyphaseclinicaltrials AT donnamgraham singlecentreexperienceofpatientswithrarecancersreferredforearlyphaseclinicaltrials AT matthewkrebs singlecentreexperienceofpatientswithrarecancersreferredforearlyphaseclinicaltrials AT fionathistlethwaite singlecentreexperienceofpatientswithrarecancersreferredforearlyphaseclinicaltrials AT louisecarter singlecentreexperienceofpatientswithrarecancersreferredforearlyphaseclinicaltrials |